文献速递肝病

慢性肝病患者感染COVID-19后进展性胆汁淤积及硬化性胆管炎为常见并发症

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease.
PubMed 文献 · Hepatology · 2022-06-18

研究纳入2020年3月至2021年7月住院的COVID-19患者,按有无慢性肝病(CLD)分层,并设非COVID-19肺炎的CLD对照。结果显示CLD患者COVID-19相关肝损伤更常见(24.6% vs 10.6%,p=0.001),感染后碱性磷酸酶和γ-谷氨酰转移酶进行性升高,23.1%发生胆汁淤积性肝衰竭,15.4%发生继发性硬化性胆管炎(SSC),SSC在CLD合并COVID-19者中较非COVID-19肺炎对照更常见(p=0.040)。

要点

  • CLD患者COVID-19相关肝损伤发生率高于无CLD者(24.6% vs 10.6%,p=0.001)。
  • CLD患者感染后碱性磷酸酶和γ-谷氨酰转移酶进行性升高,分别从91.0升至175.0 U/L和从95.0升至202.0 U/L。
  • 15.4%的CLD患者发生SSC,且SSC在COVID-19合并CLD者中较非COVID-19肺炎对照更常见(p=0.040)。

核心结论

  • 约20%的CLD患者在SARS-CoV-2感染后出现进展性胆汁淤积。
  • NAFLD/NASH及代谢危险因素患者尤其易在COVID-19后发生胆汁淤积性肝衰竭和/或SSC。

研究设计与样本

  • 纳入2020年3月至2021年7月住院的COVID-19患者,按无CLD、非晚期CLD(non-ACLD)和晚期CLD(ACLD)分层。
  • 设CLD合并非COVID-19肺炎的匹配对照队列,共纳入496例患者。
  • 记录SARS-CoV-2感染前(Pre)及感染后第1、2、3次采血(T1-T3)和最后可用时间点(last)的肝功能指标。

主要发现

  • 13.1%(n=65)患者有CLD,其中非晚期CLD占70.8%、晚期CLD占29.2%,主要病因为NAFLD/NASH(60.0%)。
  • CLD患者COVID-19相关肝损伤较无CLD者更常见(24.6% vs 10.6%,p=0.001)。
  • CLD患者感染后碱性磷酸酶进行性升高(Pre:91.0 vs T1:121.0 vs last:175.0 U/L,p<0.001)。
  • CLD患者感染后γ-谷氨酰转移酶进行性升高(Pre:95.0 vs T1:135.0 vs last:202.0 U/L,p=0.001)。
  • 23.1%(n=15/65)CLD患者发生胆汁淤积性肝衰竭(胆汁淤积加胆红素≥6 mg/dl),15.4%(n=10/65)发生SSC;SSC在CLD合并COVID-19者中较CLD合并非COVID-19肺炎者更常见(p=0.040)。

关键数值与推荐

  • CLD患者碱性磷酸酶从Pre 91.0 U/L升至T1 121.0 U/L、last 175.0 U/L(p<0.001)。
  • CLD患者γ-谷氨酰转移酶从Pre 95.0 U/L升至T1 135.0 U/L、last 202.0 U/L(p=0.001)。
  • 胆汁淤积性肝衰竭发生于23.1%(n=15/65)CLD患者;SSC发生于15.4%(n=10/65)CLD患者,COVID-19组与非COVID-19肺炎对照组比较p=0.040。
  • ACLD患者肝功能失代偿发生率26.3%(n=5/19)。

临床怎么用

  • 原文未据此给出临床推荐。
  • 原文结论指出NAFLD/NASH及代谢危险因素患者COVID-19后发生胆汁淤积性肝衰竭和/或SSC风险较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cholestasis is associated with disease severity and worse outcome in COVID-19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been described. APPROACH AND RESULTS: Hospitalized patients with COVID-19 between 03/2020 and 07/2021 were included. Patients were stratified as having (i) no chronic liver disease (CLD), (ii) non-advanced CLD (non-ACLD), or (iii) advanced CLD (ACLD). Patients with CLD and non-COVID-19 pneumonia were matched to patients with CLD and COVID-19 as a control cohort. Liver chemistries before (Pre) and at first, second, and third blood withdrawal after SARS-CoV-2 infection (T1-T3) and at last available time point (last) were recorded. A total of 496 patients were included. In total, 13.1% (n = 65) had CLD (non-ACLD: 70.8%; ACLD: 29.2%); the predominant etiology was NAFLD/NASH (60.0%). COVID-19-related liver injury was more common among patients with CLD (24.6% vs. 10.6%; p = 0.001). After SARS-CoV-2 infection, patients with CLD exhibited progressive cholestasis with persistently increasing levels of alkaline phosphatase (Pre: 91.0 vs. T1: 121.0 vs. last: 175.0 U/L; p < 0.001) and gamma-glutamyl transferase (Pre: 95.0 vs. T1: 135.0 vs. last: 202.0 U/L; p = 0.001). A total of 23.1% of patients with CLD (n = 15/65) developed cholestatic liver failure (cholestasis plus bilirubin ≥6 mg/dl) during COVID-19, and 15.4% of patients (n = 10/65) developed SSC. SSC was significantly more frequent among patients with CLD and COVID-19 than in patients with CLD and non-COVID-19 pneumonia (p = 0.040). COVID-19-associated SSC occurred predominantly in patients with NAFLD/NASH and metabolic risk factors. A total of 26.3% (n = 5/19) of patients with ACLD experienced hepatic decompensation after SARS-CoV-2 infection. CONCLUSIONS: About 20% of patients with CLD develop progressive cholestasis after SARS-CoV-2 infection. Patients with NAFLD/NASH and metabolic risk factors are at particular risk for developing cholestatic liver failure and/or SSC after COVID-19.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hartl L, Haslinger K, Angerer M, et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. Hepatology. 2022. PMID: 35596929. doi:10.1002/hep.32582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。